- Home
- WFRD vs PCVX Comparison
WFRD vs PCVX Comparison
Compare WFRD & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WFRD
- PCVX
- Stock Information
- Founded
- WFRD 1941
- PCVX 2013
- Country
- WFRD United States
- PCVX United States
- Employees
- WFRD N/A
- PCVX N/A
- Industry
- WFRD Metal Fabrications
- PCVX Biotechnology: Pharmaceutical Preparations
- Sector
- WFRD Industrials
- PCVX Health Care
- Exchange
- WFRD Nasdaq
- PCVX Nasdaq
- Market Cap
- WFRD 4.1B
- PCVX 4.0B
- IPO Year
- WFRD N/A
- PCVX 2020
- Fundamental
- Price
- WFRD $64.14
- PCVX $31.23
- Analyst Decision
- WFRD Strong Buy
- PCVX Strong Buy
- Analyst Count
- WFRD 7
- PCVX 8
- Target Price
- WFRD $92.71
- PCVX $114.17
- AVG Volume (30 Days)
- WFRD 790.9K
- PCVX 1.5M
- Earning Date
- WFRD 10-21-2025
- PCVX 11-04-2025
- Dividend Yield
- WFRD 1.56%
- PCVX N/A
- EPS Growth
- WFRD N/A
- PCVX N/A
- EPS
- WFRD 6.50
- PCVX N/A
- Revenue
- WFRD $5,147,000,000.00
- PCVX N/A
- Revenue This Year
- WFRD N/A
- PCVX N/A
- Revenue Next Year
- WFRD $0.81
- PCVX N/A
- P/E Ratio
- WFRD $9.87
- PCVX N/A
- Revenue Growth
- WFRD N/A
- PCVX N/A
- 52 Week Low
- WFRD $36.74
- PCVX $27.66
- 52 Week High
- WFRD $98.21
- PCVX $121.06
- Technical
- Relative Strength Index (RSI)
- WFRD 61.34
- PCVX 50.95
- Support Level
- WFRD $61.20
- PCVX N/A
- Resistance Level
- WFRD $64.28
- PCVX $33.32
- Average True Range (ATR)
- WFRD 2.19
- PCVX 1.15
- MACD
- WFRD -0.18
- PCVX -1.07
- Stochastic Oscillator
- WFRD 74.88
- PCVX 92.75
About WFRD Weatherford International plc
Weatherford International provides diversified oilfield services across international markets for an array of oilfield types. The firm is a global market leader in artificial lift and tubular running services. Other key product lines include cementing products, directional drilling, and wireline evaluation.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.